Inflammation-driven synaptic dysfunction is emerging as a prominent pathogenic mechanism in multiple sclerosis (MS). Importantly, synaptic alterations and synaptic loss are potentially reversible, making them potential therapeutic targets. This Review draws on studies in patients with MS and in animal models of the disease to discuss the synaptic alterations in MS and the most promising drugs to restore synaptic function and intervene in the disease progression.
- Georgia Mandolesi
- Antonietta Gentile
- Diego Centonze
